AstraZeneca news

AstraZeneca

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, an American biopharmaceutical company at the clinical stage of development. CinCor Pharma is developing new treatments for resistant and uncontrolled hypertension, as well as chronic kidney disease. The deal will amount to $1.8 billion.

AstraZeneca

AstraZeneca is acquiring TeneoTwo, which is developing TNB-486 to treat relapsed and refractory B-cell non-Hodgkin's lymphoma. AstraZeneca will pay an upfront payment of $100 million and will pay up to $805 million more when certain development milestones are reached and up to $360 million when certain sales levels are reached. The deal is scheduled to close...

AstraZeneca

AstraZeneca's COVID-19 vaccine, Vaxzevria, has been approved for use in the EU as a third dose for adult revaccination. The vaccine can now be used as a booster after two doses of the company's vaccine or by those who were previously vaccinated with mRNA vaccine made by Pfizer and BioNTech or Moderna.

AstraZeneca

AstraZeneca's IFRS net income for 3 months of 2022 was $0.388 billion, down four times from $1.562 billion in the previous year. Revenue increased by 55.6% to $11.39 billion compared to $7.32 billion a year earlier.

AstraZeneca

AstraZeneca has received approval from the British regulator for Evusheld to treat COVID-19. The drug is intended for adults with a weak immune response to the disease. Evusheld is already approved in the United States.

AstraZeneca

FDA declined to expand the scope of AstraZeneca's asthma drug Fasenra. The regulator requested additional clinical trial data on the drug in the treatment of chronic rhinosinusitis with nasal polyps.

AstraZeneca

AstraZeneca's board of directors has declared a quarterly dividend of $0.985 per share. The last day to purchase securities to receive the dividend is Feb. 23, 2022. The annual dividend yield could be 2.51%.

AstraZeneca

AstraZeneca's IFRS net income for 2021 was $0.115 billion, down 27.3 times from $3.144 billion in the previous year. Revenue increased 40.6% to $37.417 billion compared to $26.617 billion a year earlier.

AstraZeneca

U.S. government has ordered another 500,000 doses of Evushheld from AstraZeneca. The batch is expected to be delivered in Q1 2022. Previously, the government had already ordered 700,000 doses of Evushheld.

AstraZeneca

AstraZeneca has completed the sale of the rights to the drugs Eklira and Duaklir to Covis Pharma. As part of the deal, Covis Pharma paid AstraZeneca $270 million and will also cover some ongoing drug development costs.